An aqueous dispersion includes precrosslinked organopolysiloxanes, emulsifiers, and water. The precrosslinked organopolysiloxanes include units of the formula R.sub.2SiO.sub.2/2 (I), and on average at least one structural unit of the formula SiR.sup.1O.sub.2/2—Y—SiR.sup.1O.sub.2/2 (III) where Y is a divalent radical of the formula —R.sup.2—[NR.sup.3—R.sup.4—].sub.nNR.sup.3—C(O)—C(O)—NR.sup.3—Z—NR.sup.3—C(O)—C(O)—NR.sup.3—[R.sup.4—NR.sup.3—].sub.nR.sup.2—.

Provided are methods for linking polypeptides (including peptides and proteins) to other moieties using radical imitated thiol-ene chemistries, for example, modifying a polypeptide by introducing reactive thiol groups and reacting the thiol groups with olefin-containing reagents or alkyne-containing reagents under conditions that support radical thiol-ene or thiol-yne reactions. The reactive thiol groups have greater activity for radical thiol-ene reactions that a cysteine thiol group, including thiol groups that are separated from the peptide backbone by at least two carbon atoms, for example, the thiol group of a homocysteine residue. Also provided are compositions and biomaterials containing the linked polypeptides, for example, peptide and protein conjugates, and thiol-ene based biocompatible hydrogel polymers, and their uses in the medical field.

Provided is a curable composition which can form a cured product having good balance between mechanical properties, such as elongation at break and breaking strength, and weatherability, and which has excellent storage stability. A curable composition contains a (meth)acrylic polymer (A) which is a polymer of starting components including a polymerizable monomer containing 20% by mass or more of a (meth)acrylic acid alkyl ester (a1) having an alkyl group with 8 to 12 carbon atoms, and a mercapto group-containing compound (a10) having a group represented by a specific formula (1) in an amount of 0.1 to 5 parts by mass relative to 100 parts by mass of the polymerizable monomer; and a polymer (B) having a group represented by a specific formula (2) and having a polyether skeleton in the main chain thereof.

Disclosed herein are embodiments of a polymer-based implant and methods of making and using the same. The polymer-based implant comprises a polymer component and a therapeutic agent. In some embodiments, the polymer-based implant can be used to treat and/or prevent retinal diseases and/or retinopathies. The polymer-based implant exhibits physical properties that provide the ability to safely place the polymer-based implant in an ocular region without undesired diffusion and also to allow for controlled and timely release of the therapeutic agent to a desired region of the ocular region, such as the retina. In particular disclosed embodiments, the polymer-based implant can be used for safe and effective gene therapy.

A composite material includes, by weight, 50-70 parts of polyol; 15-35 parts of polyether polyol; 0.5-1.5 parts of a polyester pigment or water-based resin-free pigment having a particle size of 100-500 meshes; 2.7-3.4 parts of silicone oil; 0.1-0.3 parts of a crosslinking agent; 0.1-0.3 parts of a catalyst; 2-6 parts of water; and 0.2-0.7 parts of graphene quantum dots (GQDs).

The present invention relates to the use of at least one tetrafunctional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.

This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

The present invention relates to compositions comprising novel (per)fluoropolyether polymers, endowed with antimicrobial properties, to methods for the manufacture thereof and to their use to provide compositions having antimicrobial properties.

The curable composition is a curable composition containing an oxyalkylene polymer A having a reactive silicon group represented by —SiR.sub.a(X).sub.3-a, wherein the oxyalkylene polymer A has 6 or more terminal groups per molecule; the terminal group contains at least one selected from the group consisting of a reactive silicon group represented by —SiR.sub.a(X).sub.3-a, an active hydrogen-containing group, and an unsaturated group; the oxyalkylene polymer A has 0.3 or more reactive silicon groups per terminal group; and the number average molecular weight of the oxyalkylene polymer A is more than 25,000 and not more than 100,000.

A polyisoindolinone includes 1-100 mole percent of isoindolinone ether ketone units of the formula A; and 0-99 mole percent of arylene ether ketone units of the formula B wherein the variables are as defined herein; and wherein when the polyisoindolinone is a poly(isoindolinone ether ether ketone), it has a least one, preferably at least two, preferably all of the following properties: a glass transition temperature greater than 150° C., or 150-270° C. as determined by differential scanning calorimetry, less than 25 weight percent solubility at 23° C. in dichloromethane, orthodichlorobenzene, or chloroform, or substantially no blue phosphorescence in response to irradiation with ultraviolet light of 320-400 nm.

##STR00001##